Type 2 Diabetes Clinical Trial
Official title:
Laparoscopic Bariatric Surgery for Treatment of Type 2 Diabetes in Obese Patients With End Organ Damage: A Prospective Randomized Controlled Pilot Study
Verified date | April 2016 |
Source | McMaster University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
A large number of research studies on people who were morbidly obese (extremely overweight),
and had bariatric surgery (anti-obesity surgery) have shown that patients who were diabetic
before surgery often experienced significant improvement in their diabetes following the
surgery. For some patients, blood glucose levels returned to the normal range, and they were
able to stop taking all of their diabetes medications. For others, blood glucose levels
improved, allowing them to reduce their diabetes medications.
This research study is being done to determine whether bariatric surgery can safely provide
better control of diabetes symptoms in obese diabetics than continuing medical management
(anti-diabetic drugs in combination with diet and lifestyle changes).
There are several different types of bariatric surgery currently being used to treat morbid
obesity. Two of the most common techniques are gastric bypass and adjustable gastric
banding. This study will be comparing these two surgical techniques to treatment with a
combination of drugs, diet, and lifestyle changes for control of type 2 diabetes.
Status | Terminated |
Enrollment | 20 |
Est. completion date | April 2015 |
Est. primary completion date | April 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Residents of Southern Ontario, Canada - Obese (BMI 30 to < 40 kg/m2) patients who have had type 2 diabetes mellitus for more than 5 years, complicated by at least one of the following situations that persist despite adequate management efforts. The complicating situations are: - Severely reduced quality of life as assessed by the Audit of Diabetes Dependent Quality of Life (ADDQoL) questionnaire - Metabolic lability/instability, characterized by two or more episodes of severe hypoglycemia (= 3mmol/L) or severe hyperglycemia (= 25 mmol/L), or two or more hospital visits for diabetic complications over the last year - Despite efforts at optimal glucose control, progressive secondary complications of diabetes as defined by: - Retinopathy — a minimum of a three step progression using the Early Treatment Diabetic Retinopathy Study (ETDRS) grading system, or an equivalent progression as certified by an ophthalmologist familiar with diabetic retinopathy or - Nephropathy — persistent or progressive macroalbuminuria (>20 mg albumin/mmol creatinine) over at least 12 months (beginning anytime within the past two years) despite the use of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) or - Neuropathy — persistent or progressing autonomic neuropathy (gastroparesis, postural hypotension, neuropathic bowel or bladder) or persistent or progressing severe peripheral painful neuropathy not responding to usual management (e.g., tricyclics, gabapentin, or carbamazepine) Exclusion Criteria: - Less than 18 years of age or greater than 65 years of age - Unable to complete self and interviewer administered questionnaires in English - Incapable of providing informed consent - Any of the following medical conditions that may be associated with DM: - Recent positive history of myocardial infarction or coronary artery bypass graft or percutaneous transluminal angioplasty (less than 6 months) - Unstable angina pectoris - Recent clinically important ST-T changes on electrocardiogram (ECG) over the past year - Cardiac heart failure (New York Heart Association class III and IV; ejection fraction < 50%) - Frequent and persistent and unstable supra and ventricular arrhythmias, - Brain stroke, transient ischemic attack (TIA), - Major diabetic foot infections - Autonomic neuropathy resulting in orthostatic dysregulation - History of any psychiatric illness that would make the patient a poor candidate for bariatric surgery, as determined by the study psychiatrist - If female, pregnant or planning to become pregnant within next year - Clinically important cancer history (impact on either lifespan or performance of lap. bariatric surgery) - Clinically important abdominal or thoracic surgery that would impact the performance of laparoscopic bariatric procedure - Insulin dependence for more than 10 years - American Society of Anesthesiologists' classification of 4 or higher - Severe gastrointestinal reflux disease with Grade 3 or 4 esophagitis - History of pulmonary embolism or deep vein thrombosis - Presently taking either high-dose steroids or anticoagulants - Advanced nephropathy (Stage 4 or 5 - eGFR less than 30 ml/min) - Any other condition that, in the opinion of the study surgeons, would make the patient a poor candidate for bariatric surgery |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | St. Joseph's Healthcare | Hamilton | Ontario |
Lead Sponsor | Collaborator |
---|---|
Hamilton Health Sciences Corporation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diabetic control as assessed by HbA1c | 1 year | No | |
Secondary | Resolution of diabetes | 1 year | No | |
Secondary | Improvement in diabetic control and cardio-metabolic profile | 1 year | No | |
Secondary | Weight loss and decrease in BMI | 1 year | No | |
Secondary | Reduction in the usage of insulin or other diabetic drugs | 1 year | No | |
Secondary | Improvement in diabetic complications and end-organ damage | 1 year | No | |
Secondary | Improvement in health-related quality of life and depression scores | 1 year | No | |
Secondary | Utilization of resources and productivity losses | 1 year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |